In the absence of a submission from the holder of the marketing authorisation:
panitumumab (Vectibix®)is not recommended for use within NHS Scotland.
Indication under review: treatment of patients with wild-type KRAS metastatic colorectal cancer (mCRC) in first-line in combination with FOLFOX; in second-line in combination with FOLFIRI for patients who have received first-line fluoropyrimidine-based chemotherapy (excluding irinotecan).
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice38KB (PDF)
- Medicine name:
- panitumumab (Vectibix)
- SMC ID:
- Metastatic colorectal cancer (mCRC)
- Pharmaceutical company
- Amgen Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Non submission
- Date advice published
- 13 February 2012